Cat. No. |
Product Name |
Information |
PC-43070 |
Efonidipine hydrochloride monoethanolate
|
Efonidipine (NZ-105) is a potent, dual T-type and L-type calcium channel blocker, exhibits antihypertensive effect through vasodilatation. |
PC-43069 |
Efonidipine
|
Efonidipine (NZ-105) is a potent, dual T-type and L-type calcium channel blocker, exhibits antihypertensive effect through vasodilatation. |
PC-43065 |
GV-58
|
GV-58 is a potent, selective N-Type and P/Q-type Ca2+ Channel agonist with EC50 of 7.2 and 8.8 uM, shows no acitivity for L-type calcium channels (EC50>100 uM). |
PC-62318 |
Tetrandrine
|
Tetrandrine (NSC 77037. |
PC-61834 |
Imagabalin hydrochloride
|
Imagabalin (PD 0332334) is a novel ligand for the α2δ subunit of the voltage-dependent calcium channel (VDCC) with some selectivity for the α2δ1 subunit over α2δ2. |
PC-61833 |
Imagabalin
|
Imagabalin (PD 0332334) is a novel ligand for the α2δ subunit of the voltage-dependent calcium channel (VDCC) with some selectivity for the α2δ1 subunit over α2δ2. |
PC-61832 |
Atagabalin
|
Atagabalin (PD 0200390) is a novel ligand of the voltage-dependent calcium channel (VDCC) α2δ subunit (1 and 2) for treatment for insomnia.. |
PC-61779 |
SERCA2a activator A
|
SERCA2a activator A is a novel sarco/endoplasmic reticulum Ca2+-dependent ATPase 2a (SERCA2a) activator that activates the Ca2+-dependent ATPase activity of cardiac SR vesicles but not that of skeletal muscle SR vesicles that lack of phospholamban (PLN). |
PC-60979 |
AMG1
|
A novel specific CRAC channel inhibitor that blocks function of effector but not regulatory T cells in vitro and attenuates the pogression and severity of EAE in vivo. |
PC-60224 |
Synta-66
|
A potent, selective CRAC channel Orai1 blocker with IC50 of 3 uM. |
PC-60006 |
A-1048400
|
A novel potent, selective, orally active N-type and T-type calcium channel blocker with IC50 of 1.4 and 1.2 uM, respectively. |
PC-44016 |
Dantrolene sodium
|
A postsynaptic muscle relaxant that inhibits Ca2+ ions release from sarcoplasmic reticulum stores. |